Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations. (April 2016)

• Record Type: Journal Article
• Authors: Nishihori, Taiga; Al-Kadhimi, Zaid; Hamadani, Mehdi; Kharfan-Dabaja, Mohamed A
• Is Part Of: Immunotherapy. Volume 8:Number 4(2016:Apr.)
• Page Start: 435
• Page End: 447
• Publication Date: 2016-04
• Subjects: ATG -- GVHD -- pharmacokinetics -- T-cell depletion; Immunotherapy -- Periodicals; 615.37
• DOI: 10.2217/imt.15.128
• Languages: English
• ISSNs: 1750-743X

Abstract

Significant advances have been made in allogeneic hematopoietic cell transplantation by reducing toxicities and optimizing its efficacy. Antithymocyte globulin (ATG) is an important in vivo T-cell depletion strategy, which reduces the risk of graft-versus-host disease in HLA-matched or -mismatched donor allografting. ATG effectively targets alloreactive T cells at the expense of potentially increasing the risk of post-hematopoietic cell transplantation infections and delayed immune reconstitution. We summarize the targets, mechanisms, various preparations of ATG, the growing role of ATG in prevention of graft-versus-host disease in various transplant modalities as well as emerging data on pharmacokinetic modeling for individualized ATG dosing. Further research is needed to optimize the ATG administration while minimizing the toxicities.